Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 3.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 402,208 shares of the medical equipment provider's stock after selling 14,085 shares during the period. Douglas Lane & Associates LLC owned 0.20% of Zimmer Biomet worth $42,485,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZBH. Dunhill Financial LLC boosted its position in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 218 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of Zimmer Biomet during the 3rd quarter worth approximately $28,000. Bangor Savings Bank purchased a new stake in shares of Zimmer Biomet in the third quarter valued at approximately $31,000. Brooklyn Investment Group acquired a new stake in shares of Zimmer Biomet in the third quarter valued at approximately $35,000. Finally, Quarry LP acquired a new position in Zimmer Biomet during the second quarter worth $53,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Stock Down 1.7 %

ZBH stock traded down $1.72 during midday trading on Wednesday, hitting $101.41. The company's stock had a trading volume of 2,385,607 shares, compared to its average volume of 1,582,141. The firm has a 50-day simple moving average of $108.36 and a 200-day simple moving average of $108.14. The firm has a market capitalization of $20.19 billion, a P/E ratio of 19.28, a PEG ratio of 1.96 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 52-week low of $100.67 and a 52-week high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet's revenue was up 4.1% compared to the same quarter last year. During the same period last year, the business posted $1.65 earnings per share. As a group, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be paid a $0.24 dividend. The ex-dividend date is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.95%. Zimmer Biomet's dividend payout ratio is currently 18.25%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Canaccord Genuity Group cut their target price on Zimmer Biomet from $120.00 to $115.00 and set a "hold" rating for the company in a research note on Tuesday, September 10th. Oppenheimer cut their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating for the company in a research report on Tuesday, October 15th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Barclays cut their price target on shares of Zimmer Biomet from $125.00 to $118.00 and set an "underweight" rating for the company in a report on Thursday, December 12th. Finally, Evercore ISI reduced their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating on the stock in a research report on Tuesday, October 1st. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $123.33.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.